Calcitonin Gene-Related Peptide Receptor Antagonist Global Market Report 2025
상품코드:1810845
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 2029년에는 CAGR 11.0%로 34억 8,000만 달러로 성장할 것입니다. 예측 기간의 성장은 규제 당국의 승인, 연구 자금 증가, 혁신적인 편두통 예방 요법의 채택 증가, 노인 인구 증가 등에 기인합니다. 이 기간 동안 예상되는 주요 동향으로는 경구용 저분자 치료제 개발, 착용형 트리거식 투여 장치, 장시간 작용하는 주사제, 나노입자 기반 약물전달 시스템, 유전자 치료 접근법에 대한 진행 중인 연구 등을 들 수 있습니다.
편두통의 유병률 증가는 향후 몇 년 동안 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장의 성장을 촉진할 것으로 예상됩니다. 편두통은 종종 머리 한쪽에 국한된 욱신거리는 통증이 특징인 심한 두통입니다. 편두통 환자의 증가는 바쁜 도시 생활로 인한 스트레스 증가, 불규칙한 수면 패턴, 더 많은 사람들이 도시로 이주함에 따라 소음, 공해, 밝은 빛에 노출된 것이 원인으로 꼽힙니다. 칼시토닌 유전자 관련 펩타이드 수용체 길항제는 편두통 발작 시 혈관을 확장시키고 통증 신호를 전달하는 단백질인 CGRP를 차단하여 두통의 통증 및 관련 증상을 완화하는 작용을 합니다. 예를 들어, 국립 의학 도서관이 2024년 4월에 발표한 보고서에 따르면, 미국에서는 2022년에 약 61,204명이 편두통 진단을 받았으며, 2021년 대비 5.5% 증가하였습니다. 이러한 편두통 발생률의 증가는 CGRP 수용체 길항제 시장 확대에 박차를 가하고 있습니다.
칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장의 주요 기업들은 경구용 CGRP 수용체 길항제를 포함한 혁신적인 치료제의 승인에 중점을 두고 있으며, 편두통 치료 효과 향상, 치료 용도 확대, 보다 편리한 투여 방법의 제공을 목표로 하고 있습니다. 경구용 CGRP 수용체 길항제는 편두통과 관련된 단백질인 CGRP를 차단하여 편두통 예방에 도움이 되는 저분자 약물입니다. 예를 들어, 2023년 4월 미국 생명공학 기업 애브비는 미국 식품의약국(FDA)으로부터 성인 만성 편두통 치료제로 QULIPTA(atogepant)를 승인받았습니다. 큐리프타는 1일 1회 경구용 CGRP 수용체 길항제로 성인 편두통의 예방적 치료를 목적으로 하는 경구용 CGRP 수용체 길항제이며, 미국에서는 편두통과 만성 편두통 모두에 대한 승인을 받았습니다. 이 약은 편두통 발작 시 상승하여 통증 신호전달과 뇌의 염증에 관여하는 단백질인 CGRP를 억제하여 작용합니다. QULIPTA는 10mg, 30mg, 60mg 정제가 있으며, 60mg 용량은 특히 만성 편두통 예방에 효과가 있는 것으로 평가되고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 : 성장률 분석
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 실적 : 규모와 성장, 2019-2024
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
소분자 길항제
단클론항체
펩타이드 기반 길항제
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 : 약제 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
Zavegepant
Ubrogepant
Olcegepant
Telcegepant
Rimegepant
기타 약물 종류
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
편두통 치료
통증 관리
심혈관질환
골질환
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
클리닉
재택 케어 설정
제약회사
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 : 하위 세분화 저분자 길항제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구소분자 길항제
비강내소분자 길항제
주사용소분자 길항제
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 : 하위 세분화 단클론항체(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
Erenumab
Fremanezumab
Galcanezumab
Eptinezumab
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 : 하위 세분화 펩타이드계 길항제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
CGRP 프래그먼트 길항제
펩타이드 모방 CGRP 길항제
제7장 지역별·국가별 분석
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 : 경쟁 구도
칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Eli Lilly and Company
Amgen Inc.
Boehringer Ingelheim Pharma GmbH & Co. KG
Sosei Group Corporation
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Alder BioPharmaceuticals, Inc.
H. Lundbeck A/S
Otsuka Pharmaceutical Co. Ltd.
Biosynth Carbosynth
Seurat Therapeutics Inc.
Satsuma Pharmaceuticals Inc.
Allergan plc
Brise Pharmaceutical(Shanghai) Co Ltd.
Nuvie Biopharma Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 2029 : 새로운 기회를 제공하는 국가
칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 2029 : 새로운 기회를 제공하는 부문
칼시토닌 유전자 관련 펩타이드 수용체 길항제 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of medications designed to block the effects of CGRP, a molecule that plays a key role in transmitting pain signals and dilating blood vessels in order to prevent or treat migraines and cluster headaches. These drugs offer targeted relief from migraines and generally result in fewer side effects than traditional migraine treatments, thereby enhancing patient outcomes and overall quality of life.
The primary categories of CGRP receptor antagonists include small molecule antagonists, monoclonal antibodies, and peptide-based antagonists. Small molecule antagonists are low-molecular-weight compounds that inhibit specific proteins like the CGRP receptor, aiding in the prevention or reduction of migraine symptoms. Common drugs in this class include zavegepant, ubrogepant, olcegepant, telcegepant, rimegepant, and others. These medications are used across various applications, such as migraine treatment, pain management, cardiovascular conditions, and bone disorders, and are utilized by end users including hospitals, clinics, homecare settings, and pharmaceutical companies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The calcitonin gene-related peptide receptor antagonist market research report is one of a series of new reports from The Business Research Company that provides calcitonin gene-related peptide receptor antagonist market statistics, including calcitonin gene-related peptide receptor antagonist industry global market size, regional shares, competitors with a calcitonin gene-related peptide receptor antagonist market share, calcitonin gene-related peptide receptor antagonist market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin gene-related peptide receptor antagonist industry. This calcitonin gene-related peptide receptor antagonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The calcitonin gene-related peptide receptor antagonist market size has grown rapidly in recent years. It will grow from $2.06 billion in 2024 to $2.30 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. Growth during the historic period can be attributed to the expansion of clinical trials validating the efficacy of CGRP antagonists, increased global healthcare spending, higher diagnosis rates of migraine disorders, greater adoption of preventive migraine therapies, and a robust development pipeline of CGRP antagonist compounds.
The calcitonin gene-related peptide receptor antagonist market size is expected to see rapid growth in the next few years. It will grow to $3.48 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. Growth in the forecast period can be attributed to favorable regulatory approvals, increased research funding, rising adoption of innovative migraine prevention therapies, and a growing geriatric population. Key trends expected during this period include the development of oral small molecule therapies, wearable-triggered dosing devices, long-acting injectable formulations, nanoparticle-based drug delivery systems, and ongoing investigations into gene therapy approaches.
The rising prevalence of migraines is expected to drive the growth of the calcitonin gene-related peptide receptor antagonist market in the coming years. Migraines are severe headaches characterized by throbbing pain, often localized to one side of the head. The increase in migraine cases is attributed to heightened stress from hectic urban lifestyles, irregular sleep patterns, and greater exposure to noise, pollution, and bright lights as more people relocate to cities. Calcitonin gene-related peptide receptor antagonists work by blocking CGRP, a protein that causes blood vessels to widen and transmits pain signals during migraine attacks, thereby alleviating headache pain and related symptoms. For example, a report published by the National Library of Medicine in April 2024 noted that about 61,204 individuals in the US were diagnosed with migraines by a physician in 2022, marking a 5.5% increase from 2021. This growing incidence of migraines is fueling the market expansion for CGRP receptor antagonists.
Leading companies in the calcitonin gene-related peptide receptor antagonist market are emphasizing the approval of innovative therapies, including oral CGRP receptor antagonists, which aim to improve the effectiveness of migraine treatments, broaden therapeutic uses, and offer more convenient dosing options. Oral CGRP receptor antagonists are small-molecule drugs that block CGRP, a protein associated with migraine episodes, and help in migraine prevention. For instance, in April 2023, AbbVie Inc., a US biotechnology firm, received approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) to treat chronic migraine in adults. QULIPTA is an oral, once-daily CGRP receptor antagonist designed for the preventive treatment of migraines in adults, approved for both episodic and chronic migraines in the United States. It functions by inhibiting CGRP, a protein elevated during migraine attacks that contributes to pain signaling and brain inflammation. QULIPTA is available in tablet strengths of 10 mg, 30 mg, and 60 mg, with the 60 mg dosage specifically evaluated for chronic migraine prevention.
In October 2022, Pfizer Inc., a US pharmaceutical company, acquired Biohaven Pharmaceutical Holding Company Ltd. for an undisclosed amount. Through this acquisition, Pfizer intends to enhance its migraine treatment portfolio and support long-term growth by combining Biohaven's innovative therapies with Pfizer's global distribution capabilities to better serve patients worldwide. Biohaven Pharmaceutical Holding Company Ltd. is a US biopharmaceutical company specializing in calcitonin gene-related peptide receptor antagonists for migraine therapy.
Major players in the calcitonin gene-related peptide receptor antagonist market are Pfizer Inc., Merck & Co. Inc. , AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Sosei Group Corporation, Teva Pharmaceutical Industries Ltd., UCB S.A., Alder BioPharmaceuticals, Inc. , H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd., Biosynth Carbosynth , Seurat Therapeutics Inc., Satsuma Pharmaceuticals Inc., Allergan plc , Brise Pharmaceutical (Shanghai) Co Ltd., Nuvie Biopharma Inc.
North America was the largest region in the calcitonin gene-related peptide receptor antagonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in calcitonin gene-related peptide receptor antagonist report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the calcitonin gene-related peptide receptor antagonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The calcitonin gene-related peptide receptor antagonist market consists of sales of atogepant, orally disintegrating CGRP receptor, and intranasal CGRP receptor antagonist sprays. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Calcitonin Gene-Related Peptide Receptor Antagonist Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on calcitonin gene-related peptide receptor antagonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for calcitonin gene-related peptide receptor antagonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The calcitonin gene-related peptide receptor antagonist market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Small Molecule Antagonists; Monoclonal Antibodies; Peptide-Based Antagonists
2) By Drug Type: Zavegepant; Ubrogepant; Olcegepant; Telcegepant; Rimegepant; Other Drug Types
3) By Application: Migraine Treatment; Pain Management; Cardiovascular Conditions; Bone Disorders
4) By End-Users: Hospitals; Clinics; Homecare Settings; Pharmaceutical Companies
Subsegments:
1) By Small Molecule Antagonists: Oral Small Molecule Antagonists; Intranasal Small Molecule Antagonists; Injectable Small Molecule Antagonists
2) By Monoclonal Antibodies: Erenumab; Fremanezumab; Galcanezumab; Eptinezumab
3) By Peptide-Based Antagonists: CGRP Fragment-Based Antagonists; Peptidomimetic CGRP Antagonists
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc. ; AbbVie Inc.; Bristol-Myers Squibb Company; Novartis AG; Eli Lilly and Company; Amgen Inc.; Boehringer Ingelheim Pharma GmbH & Co. KG; Sosei Group Corporation; Teva Pharmaceutical Industries Ltd.; UCB S.A.; Alder BioPharmaceuticals, Inc. ; H. Lundbeck A/S; Otsuka Pharmaceutical Co. Ltd.; Biosynth Carbosynth ; Seurat Therapeutics Inc.; Satsuma Pharmaceuticals Inc.; Allergan plc ; Brise Pharmaceutical (Shanghai) Co Ltd.; Nuvie Biopharma Inc.
3. Calcitonin Gene-Related Peptide Receptor Antagonist Market Trends And Strategies
4. Calcitonin Gene-Related Peptide Receptor Antagonist Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Calcitonin Gene-Related Peptide Receptor Antagonist Growth Analysis And Strategic Analysis Framework
5.1. Global Calcitonin Gene-Related Peptide Receptor Antagonist PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.1. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule Antagonists
Monoclonal Antibodies
Peptide-Based Antagonists
6.2. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Zavegepant
Ubrogepant
Olcegepant
Telcegepant
Rimegepant
Other Drug Types
6.3. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Migraine Treatment
Pain Management
Cardiovascular Conditions
Bone Disorders
6.4. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Homecare Settings
Pharmaceutical Companies
6.5. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Sub-Segmentation Of Small Molecule Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Small Molecule Antagonists
Intranasal Small Molecule Antagonists
Injectable Small Molecule Antagonists
6.6. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Erenumab
Fremanezumab
Galcanezumab
Eptinezumab
6.7. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Sub-Segmentation Of Peptide-Based Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
CGRP Fragment-Based Antagonists
Peptidomimetic CGRP Antagonists
7. Calcitonin Gene-Related Peptide Receptor Antagonist Market Regional And Country Analysis
7.1. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Calcitonin Gene-Related Peptide Receptor Antagonist Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Calcitonin Gene-Related Peptide Receptor Antagonist Market
9.1. China Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
9.2. China Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Calcitonin Gene-Related Peptide Receptor Antagonist Market
10.1. India Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Calcitonin Gene-Related Peptide Receptor Antagonist Market
11.1. Japan Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
11.2. Japan Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Calcitonin Gene-Related Peptide Receptor Antagonist Market
12.1. Australia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Calcitonin Gene-Related Peptide Receptor Antagonist Market
13.1. Indonesia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Calcitonin Gene-Related Peptide Receptor Antagonist Market
14.1. South Korea Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
14.2. South Korea Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market
15.1. Western Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
15.2. Western Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Calcitonin Gene-Related Peptide Receptor Antagonist Market
16.1. UK Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Calcitonin Gene-Related Peptide Receptor Antagonist Market
18.1. France Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market
21.1. Eastern Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
21.2. Eastern Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Calcitonin Gene-Related Peptide Receptor Antagonist Market
22.1. Russia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Calcitonin Gene-Related Peptide Receptor Antagonist Market
23.1. North America Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
23.2. North America Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Calcitonin Gene-Related Peptide Receptor Antagonist Market
24.1. USA Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
24.2. USA Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Calcitonin Gene-Related Peptide Receptor Antagonist Market
26.1. South America Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
26.2. South America Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Calcitonin Gene-Related Peptide Receptor Antagonist Market
27.1. Brazil Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Calcitonin Gene-Related Peptide Receptor Antagonist Market
28.1. Middle East Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
28.2. Middle East Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Calcitonin Gene-Related Peptide Receptor Antagonist Market
29.1. Africa Calcitonin Gene-Related Peptide Receptor Antagonist Market Overview
29.2. Africa Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Calcitonin Gene-Related Peptide Receptor Antagonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Calcitonin Gene-Related Peptide Receptor Antagonist Market Competitive Landscape And Company Profiles
